What Larimar Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 8 |
| Sells | 0 | 0 |
| Total trades | 1 | 13 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 50,000 | 5,398,978 |
| Disposed | 0 | 0 |
| Net activity | +50,000 | +5,398,978 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Harlow John B. Jr. | President and COO | Sep 29 | Grant / award · A | +50,000 | — | — | 50,000 |
| Hamilton Thomas Edward | Director | Jul 06 | Open-market buy · P | +50,000 | $3.34 | +$167K | 714,798 |
| Sherman Jeffrey W | Director | Feb 27 | Open-market buy · P | +5,000 | $5.00 | +$25K | 5,000 |
| Hamilton Thomas Edward | Director | Feb 27 | Open-market buy · P | +100,000 | $5.00 | +$500K | 664,798 |
| Thomas Frank E | Director | Feb 27 | Open-market buy · P | +5,000 | $5.00 | +$25K | 7,000 |
| Flynn James E | Director | Feb 27 | Open-market buy · P | +2,000,000 | $5.00 | +$10M | 6,207,982 |
| Flynn James E | Director | Feb 27 | Open-market buy · P | +831,978 | $5.00 | +$4.16M | 8,153,107 |
| Flynn James E | Director | Feb 27 | Open-market buy · P | +1,084,012 | $5.00 | +$5.42M | 10,622,957 |
| Flynn James E | Director | Feb 27 | Open-market buy · P | +1,084,010 | $5.00 | +$5.42M | 10,622,928 |
| Ben-maimon Carole | President and CEO | Jan 26 | Grant / award · A | +100,100 | — | — | 368,276 |
| Clayton Russell | Chief Medical Officer | Jan 26 | Grant / award · A | +25,637 | — | — | 71,443 |
| Shankar Gopi | Chief Development Officer | Jan 26 | Grant / award · A | +25,637 | — | — | 76,443 |
| Celano Michael | Chief Financial Officer | Jan 26 | Grant / award · A | +37,604 | — | — | 215,785 |
| Flynn James E | Director | Jul 31 | Open-market buy · P | +2,599,932 | $3.20 | +$8.32M | 7,321,129 |
| Flynn James E | Director | Jul 31 | Open-market buy · P | +3,387,539 | $3.20 | +$10.8M | 9,538,945 |
| Flynn James E | Director | Jul 31 | Open-market buy · P | +3,387,529 | $3.20 | +$10.8M | 9,538,918 |
| Clayton Russell | Chief Medical Officer | Jan 22 | Grant / award · A | +23,306 | — | — | 45,806 |
| Ben-maimon Carole | President and CEO | Jan 22 | Grant / award · A | +91,000 | — | — | 387,208 |
| Shankar Gopi | Chief Development Officer | Jan 22 | Grant / award · A | +23,306 | — | — | 50,806 |
| Celano Michael | Chief Financial Officer | Jan 22 | Grant / award · A | +34,185 | — | — | 178,181 |
Loading...
